Medicinal Products

ALMOTRIPTAN ZENTIVA 125 mg

Generic drug of Almogran
Therapeutic Class: Neurology-Psychiatry
Active ingredients: Almotriptan
laboratory: Sanofi-Aventis France

Filmstrip
box of 12
All forms

Indication

Treatment of the cephalalgic phase of the migraine attack with or without aura.

Dosage ALMOTRIPTAN ZENTIVA 125 mg tablet film boast of 12

Treatment of the cephalalgic phase of the migraine attack with or without aura.

Against indications

Hypersensitivity to almotriptan or any of the excipients listed in the Composition section.

As with other 5-hydroxytryptamine (5-HT 1B / 1D ) receptor agonists, almotriptan should not be used in patients with anties, symptoms or signs of cardiac pathology. ischemic (myocardial infarction, angina pectoris, documented silent ischemia, Prinzmetal's angina) or with severe hypertension or benign or moderate hypertension not controlled.

Almotriptan should not be used in patients with prior history of stroke or transient ischemic attack (TIA) or in patients with peripheral vascular disease.

Concomitant administration of almotriptan with ergotamine, ergotamine derivatives (including metathysergide) or other 5-hydroxytryptamine (5-HT 1B / 1D ) receptor agonists ) is contraindicated.

Administration of almotriptan is contraindicated in patients with severe hepatic insufficiency (see Dosage and Method of Administration ).

Adverse effects Almotriptan Zentiva

Almotriptan has been evaluated in more than 2, 700 patients in clinical trials of up to one year. The most common undesirable effects at the therapeutic dose were: dizziness, drowsiness, nausea, vomiting and fatigue. None of these undesirable effects occurred at a frequency greater than 1.5%.

In the list below are the undesirable effects that have occurred in patients during clinical trials or after marketing.

These undesirable effects are presented by system-organ and in order of decreasing frequency.

The frequencies are defined in the following way: very frequent (≥ 1/10), frequent (≥ 1/100 - <1/10), not very frequent (≥ 1/1000 - <1/100), rare (≥ 1 / 10000 - <1/1000), very rare (<1/10000), undetermined frequency (can not be estimated with the available data).

Class organ system

FrÚquents

Few Frequent

Very rare

IndÚterminÚe

Immune system

Reactions of hypersensitivity (including angioedeals)

Anaphylactic reactions

Central Nervous System

Dizziness, Sleepiness

Paresthes, Cèphalès

convulsions

Eye disorders

Visual impairment *

Blurry vision*

Auditory and vestibular apparatus

AcouphÞnes

Cardiovascular system

Palpitations.

Vasospasm of coronary arteries. Myocardial infarction. Tachycardia.

Respiratory system, thorax and mediastinum

Feeling of tight throat.

Digestive system

NausÚe

Vomiting

Diarrhea, Dyspepsia, Dryness of the mouth.

Musculoskeletal system, connective tissue

myalgia

Bone pain.

General disorders

Tired

AsthÚnie

Pain in the chest.

* However, visual disturbances can also occur during the migraine attack itself.

Declaration of suspected undesirable effects

The declaration of undesirable effects suspected after authorization of the drug is important. It allows continuous monitoring of the beneficial / risk ratio of the drug. Healthcare professionals declare any suspected adverse effects via the national system of declaration: National Agency for the Safety of Medicines and Health Products (ANSM) and the Network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr.

Popular Posts

Category Medicinal Products, Next Article